ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression
Zijiang Yang,Aiqin Gao,Wenjing Shi,Jingnan Wang,Xianchao Zhang,Zhengyan Xu,Tingting Xu,Yan Zheng,Yuping Sun,Fei Yang
DOI: https://doi.org/10.2147/OTT.S290348
IF: 4
2021-07-20
OncoTargets and Therapy
Abstract:Zijiang Yang, 1, &ast Aiqin Gao, 2, &ast Wenjing Shi, 1 Jingnan Wang, 1 Xianchao Zhang, 3 Zhengyan Xu, 3 Tingting Xu, 3 Yan Zheng, 4 Yuping Sun, 5 Fei Yang 3 1 Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250013, People's Republic of China; 2 Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, 250117, People's Republic of China; 3 Department of Pathology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250013, People's Republic of China; 4 Research Center of Translational Medicine, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250013, People's Republic of China; 5 Proton Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, 250117, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fei Yang Department of Pathology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250013, People's Republic of China Tel +86 13370586609 Email Purpose: Immune checkpoint blockade (ICB) therapy shows little or no clinical benefit in most colorectal cancer (CRC) patients, due to the immunosuppressive T cell contexture in the tumor microenvironment (TME). Immunoglobulin-like transcript (ILT) 4 is an immunosuppressive molecule in myeloid cells. ILT4 is enriched in solid tumor cells, facilitating their proliferation, invasion, and metastasis. However, the regulatory role of ILT4 in T cell immunity of CRC is still undetermined. Here, we aimed to explore how tumor cell-derived ILT4 orchestrates T cell infiltration, subset distribution, and function in CRC. Methods: A total of 145 paraffin-embedded cancer tissues and the corresponding clinicopathological information were collected from CRC patients. Immunohistochemical (IHC) staining and public database analyses determined the correlation of ILT4 expression with different T cell subset densities, IFN-γ levels, and patient outcomes. Paired Ig-like receptor B (PIR-B, ILT4 mouse ortholog)-overexpressing/-downregulated MC38 cells were subcutaneously injected into C57BL/6 mice as a CRC transplantation model. The frequencies, subsets, and IFN-γ levels of T cells in mouse blood and spleens were determined using flow cytometry and immunohistochemistry, respectively. Results: High ILT4 expression in CRC cells was associated with decreased T cell infiltration, disease progression, and poor patient survival. T cell subset analyses indicated that ILT4-high patients showed reduced CD8 + T cell but elevated FOXP3 + regulatory T (Treg) cell frequencies in the TME. High ILT4 levels predicted lower IFN-γ production by tumor-infiltrating lymphocytes (TILs), especially by CD8 + T cells in human CRC tissues. Moreover, PIR-B overexpression accelerated MC38 growth in mice, decreased CD3 + /CD8 + /IFN-γ + T cell densities, and elevated Treg infiltration in the TME, blood, and spleens. PIR-B knockdown had the opposite effects. Conclusion: ILT4 in CRC cells induced immunosuppressive T cell subset infiltration and impaired IFN-γ production in TILs, suggesting that ILT4 might be a potential immunotherapeutic target and prognostic biomarker. Keywords: immunoglobulin-like transcript 4, colorectal cancer, T cell subsets, IFN-γ, immunosuppression Colorectal cancer (CRC) is the fourth most frequent and the second most deadly cancer worldwide, with an estimated 1.8 million new cases and 0.86 million deaths in 2018. 1 Its incidence is still increasing and is predicted to reach 2.5 million cases in 2035. 2 More than 60% of CRC patients are diagnosed at the stages of regional or distant metastasis, which are often incurable despite dramatic progress in comprehensive surgery, radiotherapy, and systemic treatment. 3 , 4 Immune checkpoint blockade (ICB), which targets the immunosuppressive PD-1/PD-L1/CTLA-4 pathway to resurrect T cell-mediated cancer killing, is the latest revolution in cancer therapy. Due to its durable response observed in multiple tumors, ICB is considered to be a potential curative strategy for malignancies. 5 However, only 4–5% of advanced CRC patients who have deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) may benefit from ICB. 6 The majority of CRCs are m -Abstract Truncated-
oncology,biotechnology & applied microbiology